Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME; SU2C/PCF West Coast Prostate Cancer Dream Team; Quigley DA, Feng FY, Chi KN, Wyatt AW. Herberts C, et al. Among authors: schonlau e. Nature. 2022 Aug;608(7921):199-208. doi: 10.1038/s41586-022-04975-9. Epub 2022 Jul 20. Nature. 2022. PMID: 35859180
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.
Ritch E, Fu SYF, Herberts C, Wang G, Warner EW, Schönlau E, Taavitsainen S, Murtha AJ, Vandekerkhove G, Beja K, Loktionova Y, Khalaf D, Fazli L, Kushnir I, Ferrario C, Hotte S, Annala M, Chi KN, Wyatt AW. Ritch E, et al. Among authors: schonlau e. Clin Cancer Res. 2020 Mar 1;26(5):1114-1125. doi: 10.1158/1078-0432.CCR-19-1623. Epub 2019 Nov 19. Clin Cancer Res. 2020. PMID: 31744831
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, Lin D, Gleave A, Yip S, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, Vandekerkhove G, Ritch E, Warner E, Saad F, Iqbal N, Nykter M, Gleave ME, Wang Y, Annala M, Chi KN, Wyatt AW. Herberts C, et al. Among authors: schonlau e. Eur Urol. 2020 Dec;78(6):834-844. doi: 10.1016/j.eururo.2020.04.058. Epub 2020 May 22. Eur Urol. 2020. PMID: 32451180
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.
Warner E, Herberts C, Fu S, Yip S, Wong A, Wang G, Ritch E, Murtha AJ, Vandekerkhove G, Fonseca NM, Angeles A, Beigi A, Schönlau E, Beja K, Annala M, Khalaf D, Chi KN, Wyatt AW. Warner E, et al. Among authors: schonlau e. Clin Cancer Res. 2021 Mar 15;27(6):1650-1662. doi: 10.1158/1078-0432.CCR-20-3708. Epub 2021 Jan 7. Clin Cancer Res. 2021. PMID: 33414135
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.
Annala M, Fu S, Bacon JVW, Sipola J, Iqbal N, Ferrario C, Ong M, Wadhwa D, Hotte SJ, Lo G, Tran B, Wood LA, Gingerich JR, North SA, Pezaro CJ, Ruether JD, Sridhar SS, Kallio HML, Khalaf DJ, Wong A, Beja K, Schönlau E, Taavitsainen S, Nykter M, Vandekerkhove G, Azad AA, Wyatt AW, Chi KN. Annala M, et al. Among authors: schonlau e. Ann Oncol. 2021 Jul;32(7):896-905. doi: 10.1016/j.annonc.2021.03.205. Epub 2021 Apr 6. Ann Oncol. 2021. PMID: 33836265 Free article. Clinical Trial.
Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer.
Fonseca NM, Van der Eecken K, Herberts C, Verbeke S, Ng SWS, Lumen N, Ritch E, Murtha AJ, Bernales CQ, Schönlau E, Moris L, Van Dorpe J, Annala M, Wyatt AW, Ost P. Fonseca NM, et al. Among authors: schonlau e. JCO Precis Oncol. 2022 Apr;6:e2100543. doi: 10.1200/PO.21.00543. JCO Precis Oncol. 2022. PMID: 35507889
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.
Warner EW, Van der Eecken K, Murtha AJ, Kwan EM, Herberts C, Sipola J, Ng SWS, Chen XE, Fonseca NM, Ritch E, Schönlau E, Bernales CQ, Donnellan G, Munzur AD, Parekh K, Beja K, Wong A, Verbeke S, Lumen N, Van Dorpe J, De Laere B, Annala M, Vandekerkhove G, Ost P, Wyatt AW. Warner EW, et al. Among authors: schonlau e. Nat Cancer. 2024 Jan;5(1):114-130. doi: 10.1038/s43018-023-00692-y. Epub 2024 Jan 4. Nat Cancer. 2024. PMID: 38177459
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, Kwan EM, Parekh K, Schönlau E, Bernales CQ, Donnellan G, Ng SWS, Sumiyoshi T, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Miller S, Parimi S, Lavoie JM, Hardy E, Soleimani M, Nappi L, Eigl BJ, Kollmannsberger C, Taavitsainen S, Nykter M, Tolmeijer SH, Boerrigter E, Mehra N, van Erp NP, De Laere B, Lindberg J, Grönberg H, Khalaf DJ, Annala M, Chi KN, Wyatt AW. Fonseca NM, et al. Among authors: schonlau e. Nat Commun. 2024 Feb 28;15(1):1828. doi: 10.1038/s41467-024-45475-w. Nat Commun. 2024. PMID: 38418825 Free PMC article.